{"name":"Shenyang Sunshine Pharmaceutical Co., LTD.","slug":"shenyang-sunshine-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"shenyangsunshine.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"EPIAO®","genericName":"EPIAO®","slug":"epiao","indication":"Other","status":"marketed"},{"name":"SSGJ-709","genericName":"SSGJ-709","slug":"ssgj-709","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TPO","genericName":"TPO","slug":"tpo","indication":"Immune thrombocytopenia (ITP)","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"PD-1 Inhibitor + Chemotherapy","genericName":"PD-1 Inhibitor + Chemotherapy","slug":"pd-1-inhibitor-chemotherapy","indication":"Advanced or metastatic solid tumors (specific indication not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"EPIAO®","genericName":"EPIAO®","slug":"epiao","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SSGJ-709","genericName":"SSGJ-709","slug":"ssgj-709","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TPO","genericName":"TPO","slug":"tpo","phase":"marketed","mechanism":"TPO is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the thrombopoietin receptor on hematopoietic stem cells.","indications":["Immune thrombocytopenia (ITP)","Thrombocytopenia associated with chronic liver disease"],"catalyst":""},{"name":"PD-1 Inhibitor + Chemotherapy","genericName":"PD-1 Inhibitor + Chemotherapy","slug":"pd-1-inhibitor-chemotherapy","phase":"phase_3","mechanism":"This combination therapy blocks PD-1 immune checkpoints to restore anti-tumor immunity while chemotherapy directly kills cancer cells.","indications":["Advanced or metastatic solid tumors (specific indication not publicly detailed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNZmlKVDJlSEtYNGh3QnRTZXliRFRPR3VULThBVlhJRzNZRHpsbkQwbU95bjI0aWtoUDNITXowWnc1Ny1BUEgwbGtIdk5SREhRdVpMZ2pId3BPLTdEeHlkRV9Jc3ZjVXc3SFgzYmxVRjJvbnVUNmVmMURBLUtDVU44UllmY253cXFmcER6YVlfcmhKT3dra01MN1ZXcG9SRUxfS1BDQmNEVXZIaFlOMVhJeTg3WGJUSF91MGN0bXl3?oc=5","date":"2026-03-03","type":"pipeline","source":"Weekly Voice","summary":"Resilient Roofing Solutions: The Benefits of Silicone Roof Coatings in Extreme Weather Conditions - Weekly Voice","headline":"Resilient Roofing Solutions: The Benefits of Silicone Roof Coatings in Extreme Weather Conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQMFViVERhVHoxS1pTV0JHRjREQ0tYQzNvTzkwQlFhTWVoM2VTeEp3aTR3Zm5pWjJuRmhQeU5lMzBGelBHdkw2NWZmV3FWMTRWclI1SGRGdlpLN0h5QzhTa3h5ajItWXpfMTdnNlFsY0s3THVBbzZLY1gxaWRQdWNtREs1TQ?oc=5","date":"2025-08-05","type":"pipeline","source":"BioXconomy","summary":"Eyes on Asia: GSK & Hengrui, Novatim, Pfizer - BioXconomy","headline":"Eyes on Asia: GSK & Hengrui, Novatim, Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOTkd4M1hlSHFSc3FaTk40MzhjTWZqaS1YZnFxNmRsdHRiVndUM2tVN0w3OGVpZ3daaHBBLV9RMnJGdll5OXBBNXB6WUxHbWp4eTJiUERJTHJhZTlBWUJlUjI4Qk5wTm5mam1uX0JYOUxVX2Q0UU5Jek9vNE9wTDNFcGN6TWRlSkt4d21scUI1RUd2WkNuR3JEUmp5TQ?oc=5","date":"2025-05-20","type":"pipeline","source":"BioWorld News","summary":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody - BioWorld News","headline":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQc2pJeUh3TURfWUNHbUltOU5HMFJIc3dQUFZJWks0U0ROakdpa2kwRjRDLTc3QTBsRzc0SXUwdE1SdzJTZ0hwSVJGTHBObWM2NkQzZF80bXB2djJsX0xOQjlNcVowTTFrMVRLUl9VMFJzQVlLamU0X2pNRUMxTC1PWGp5M2VqcUFNTklLRm0zS1JScXpDc3JXTDlPMHoxOUFoVjU1NnN2bUrSAa4BQVVfeXFMTXNMYy0zaUpOaEpLX3RXVkZ1NW55SWk3c0dna2RxNUpiNkVsQndTTm1nQjUtS3oyQy1UczJxYjFaOXRGN3Itb2kzaXBfMDJVWnN0QUNJdFh2dmYycXRpT0poNEFGUXhJTEJwdE1ITkxBdW8zRTZhQkVmRDJPNmdwSDFXR1MtNmpFamFCVmdJbEpHXzVXelJlcXZwZlIzWGRXRHlHek9CZVlJcjFZYzF3?oc=5","date":"2025-05-20","type":"deal","source":"Medical Dialogues","summary":"Pfizer strikes cancer drug deal with China's 3SBio - Medical Dialogues","headline":"Pfizer strikes cancer drug deal with China's 3SBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8zRm5PaXV5UGRKcUtBVUltMmVJWHJIZWNua1lxclFMbU9ZRFVBNVZLOVl0WkZiNmZrcmhaQTFxNldvWUY2TjVIVEpsVUZGNk9lN2VOc3FLSHVCcF9EcnpMN29LRzg0aEd4a0k3ZmhlR2FQajJMX1hRR2dyMA?oc=5","date":"2025-01-20","type":"deal","source":"Law.asia","summary":"Fangda Advises Duality Biologics on its collaboration with 3SBio Inc. for commercialization of HER2 ADC in Greater China region - Law.asia","headline":"Fangda Advises Duality Biologics on its collaboration with 3SBio Inc. for commercialization of HER2 ADC in Greater China","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}